SERDs Breast Cancer Treatment: Mechanism Of Action And Clinical Use

Clinical Application and Use of SERDs in Breast Cancer

The clinical application of SERDs is primarily seen in hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. Typically, fulvestrant and similar agents are prescribed for patients who have progressed on previous hormonal therapies. Administration protocols, dosing schedules, and monitoring requirements may vary depending on the specific agent chosen and the patient’s prior treatment experience.

In recent years, the introduction of oral SERDs such as elacestrant has broadened investigational and clinical options. Ongoing trials are assessing whether these agents can serve as alternatives to injectable therapies, particularly in cases where intravenous or intramuscular administration presents challenges for chronic care.

Clinical guidelines and decision-making algorithms emphasize individualized therapy planning. Factors such as tumor hormone receptor levels, patient comorbidities, previous responses to endocrine agents, and potential for drug resistance are commonly considered. The multidisciplinary nature of cancer care means oncologists, pharmacists, and patients work together to determine when a SERD fits into a treatment plan.

Many SERDs are also evaluated in combination strategies, including concurrent use with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors or mTOR inhibitors. These combination approaches are designed to target multiple pathways influencing tumor growth and have formed the basis for several active clinical trials.